Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01353742 | Lamivudine and Adefovir Dipivoxil Fixed Dose Combination | PHASE1 | COMPLETED | 40 | — | — | Feb 21, 2011 | Apr 12, 2011 | Aug 4, 2017 | 1 | Hong Kong |
| Arm | Type | Description |
|---|---|---|
| Lamivudine and Adefovir dipivoxil | ACTIVE_COMPARATOR | One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet |
| Fixed dose combination | EXPERIMENTAL | One capsule (100mg lamivudine and 10mg adefovir dipivoxil) |
| Name | Type | Description |
|---|---|---|
| Lamivudine | DRUG | 100mg tablet |
| Adefovir dipivoxil | DRUG | 10mg tablet |
| Fixed dose combination (Lamivudine and Adefovir dipivoxil) | DRUG | 100mg/10mg capsule |
Inclusion Criteria: * Healthy as determined by a responsible physician. * Male 18 and 55 years of age. * Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. * Body weight \>50 kg (110 lbs) and body mass index (BMI) between 19.0 and 25.0....